Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Rizatriptan
Drug ID BADD_D01957
Description Rizatriptan is a triptan drug used for the treatment of migraine headaches. It is a selective 5-hydroxytryptamine1 receptor subtype agonist.
Indications and Usage For treatment of acute migraine attacks with or without aura.
Marketing Status approved
ATC Code N02CC04
DrugBank ID DB00953
KEGG ID D08485
MeSH ID C093622
PubChem ID 5078
TTD Drug ID D0S9MU
NDC Product Code 33342-088; 71335-1352; 62938-0020; 65977-0067; 33342-087; 63850-7138; 63850-7119
UNII 51086HBW8G
Synonyms rizatriptan | N,N-dimethyl-2-(5-(1,2,4-triazol-1-ylmethyl)-1H-indole-3-yl)ethylamine | rizatriptan benzoate | MK 0462 | MK-0462 | MK-462 | MK 462 | L 705,126 | L-705,126 | L-705126 | L 705126 | Maxalt
Chemical Information
Molecular Formula C15H19N5
CAS Registry Number 144034-80-0
SMILES CN(C)CCC1=CNC2=C1C=C(C=C2)CN3C=NC=N3
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Hypersomnia19.02.05.001; 17.15.01.001--
Hypertension24.08.02.0010.000273%
Hypertensive crisis24.08.01.0010.000205%Not Available
Hypoaesthesia17.02.06.023; 23.03.03.0810.000368%Not Available
Hyporeflexia17.02.01.003--
Increased appetite14.03.01.003; 08.01.09.027--Not Available
Insomnia19.02.01.002; 17.15.03.0020.000436%
Intestinal ischaemia07.15.02.001; 24.04.08.0010.000136%Not Available
Irritability19.04.02.013; 08.01.03.0110.000136%
Joint swelling15.01.02.0040.000136%Not Available
Lacrimation increased06.08.02.004--
Lethargy19.04.04.004; 17.02.04.003; 08.01.01.0080.000300%
Liver disorder09.01.08.0010.000300%Not Available
Loss of consciousness17.02.04.0040.000136%Not Available
Malaise08.01.01.0030.000914%
Memory impairment19.20.01.003; 17.03.02.003--
Menopausal symptoms21.02.02.002--Not Available
Menstrual disorder21.01.01.004--Not Available
Migraine24.03.05.003; 17.14.02.0010.005142%Not Available
Migraine with aura24.03.05.005; 17.14.02.0020.000136%Not Available
Muscle spasms15.05.03.004--
Muscular weakness17.05.03.005; 15.05.06.001--
Musculoskeletal pain15.03.04.007--
Myalgia15.05.02.0010.000368%
Myocardial infarction24.04.04.009; 02.02.02.0070.000505%
Myocardial ischaemia24.04.04.010; 02.02.02.008--Not Available
Nasal dryness22.04.03.002--Not Available
Nasopharyngitis22.07.03.002; 11.01.13.002--Not Available
Nausea07.01.07.0010.005415%
Nervous system disorder17.02.10.001--Not Available
The 4th Page    First    Pre   4 5 6 7 8    Next   Last    Total 8 Pages